anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an application of pidotimod to the preparation of medicaments for treating hepatitis B. The trade name of pidotimod is Wanshining, the English name is Pidotimod, the chemical name is (R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-tetrahydrothiazole-4-carboxylic acid, the molecular formula is C9H12N2O4S, the molecular weight is 244.26, and the chemical structural formula is disclosed in the specification. As a fully chemosynthetic dipeptide immunity medicament, pidotimod is suitable for the requirements for the clinical treatment of hepatitis B. The therapeutic effects of the current antiviral medicament on patients with chronic hepatitis B are strengthened by regulating the immune system of the patients with chronic hepatitis B by pidotimod. Pidotimod has significant clinical practical application prospects. As a novel immunity regulating agent, pidotimod has the advantages of convenient operation, low cost, clear mechanism and operability. The present invention provides a novel medicament for treating chronic hepatitis B.
We present the case of a 69 years old man who was hit by a car while crossing the road. A CT scan of the skull and brain showed fracture of the left occipital bone, bilateral hemispheric subarachnoid hemorrhage, right frontal-temporal-parietal subdural hematoma with a shift of midline structures of 18 mm and complete obliteration of the third ventricle. He showed signs of anisocoria, absence of mobility of all 4 limbs and was immediately intubated and admitted to intensive care. The neurosurgeon was immediately consulted. He underwent drainage of subdural hematoma and two decompressive craniotomies, but died 15 days after the initial trauma. At autopsy, the stomach was full of a greenish poltaceous material. This gave us vital information in reconducting the actual brain death of the man to the immediacy of the investment, helping in the process of ruling out any possible profiles of professional liability.
BACKGROUND: Hypocholesterolemia hallmarks critical illness though the underlying pathophysiology is incompletely understood. As low circulating cholesterol levels could partly be due to an increased conversion to cortisol/corticosterone, we hypothesized that glucocorticoid treatment, via reduced de novo adrenal cortisol/corticosterone synthesis, might improve cholesterol availability and as such affect adrenal gland and skeletal muscle function.
METHODS: In a matched set of prolonged critically ill patients (n = 324) included in the EPaNIC RCT, a secondary analysis was performed to assess the association between glucocorticoid treatment and plasma cholesterol from ICU admission to day five. Next, in a mouse model of cecal ligation and puncture-induced sepsis, septic mice were randomized to receive either hydrocortisone (1.2 mg/day) (n = 17) or placebo (n = 15) for 5 days, as compared with healthy mice (n = 18). Plasma corticosterone, cholesterol, and adrenocortical and myofiber cholesterol were quantified. Adrenal structure and steroidogenic capacity were evaluated. Muscle force and markers of atrophy, fibrosis and regeneration were quantified. In a consecutive mouse study with identical design (n = 24), whole body composition was assessed by EchoMRI to investigate impact on lean mass, fat mass, total and free water.
RESULTS: In human patients, glucocorticoid treatment was associated with higher plasma HDL- and LDL-cholesterol from respectively ICU day two and day three, up to day five (P < 0.05). Plasma corticosterone was no longer elevated in hydrocortisone-treated septic mice compared to placebo, whereas the sepsis-induced reduction in plasma HDL- and LDL-cholesterol and in adrenocortical cholesterol was attenuated (P < 0.05), but without improving the adrenocortical ACTH-induced CORT response and with increased adrenocortical inflammation and apoptosis (P < 0.05). Total body mass was further decreased in hydrocortisone-treated septic mice (P < 0.01) compared to placebo, with no additional effect on muscle mass, force or myofiber size. The sepsis-induced rise in markers of muscle atrophy and fibrosis was unaffected by hydrocortisone treatment, whereas markers of muscle regeneration were suppressed compared to placebo (P < 0.05). An increased loss of lean body mass and total and free water was observed in hydrocortisone-treated septic mice compared to placebo (P < 0.05).
CONCLUSIONS: Glucocorticoid treatment partially attenuated critical illness-induced hypocholesterolemia, but at a cost of impaired adrenal function, suppressed muscle regeneration and exacerbated loss of body mass.
Trigonal meningiomas are rare intraventricular tumours that present a surgical challenge. There is no consensus on the optimal surgical approach to these lesions, though the transtemporal and transparietal approaches are most frequently employed. We aimed to examine the approach-related morbidity and surgical nuances in treating trigonal meningiomas. This retrospective review assimilated data from 64 trigonal meningiomas operated over 15 years. Details of clinicoradiological presentation, surgical approach and intraoperative impression, pathology and incidence of various postoperative deficits were recorded. In our study, Trigonal meningiomas most frequently presented with headache and visual deterioration. The median volume of tumours was 63.6cc. Thirty-one meningiomas each (48.4%) were WHO Grade 1 and WHO Grade 2, while 2 were WHO Grade 3. The most frequent approach employed was transtemporal (38 patients, 59.4%), followed by transparietal (22 patients, 34.4%). After surgery features of raised ICP and altered mental status resolved in all patients, while contralateral limb weakness resolved in 80%, aphasia in 60%, seizures in 70%, and vision loss in 46.2%. Eighteen patients (28.13%) developed transient postoperative neurological deficits, with one patient (1.5%) developing permanent morbidity. Surgery for IVMs results in rapid improvement of neurological status, though visual outcomes are poorer in patients with low vision prior to surgery, longer duration of complaints and optic atrophy. The new postoperative deficits in some patients tend to improve on follow up. Transtemporal and transparietal approaches may be employed, based on multiple factors like tumour extension, loculation of temporal horn, size of lesion with no significant difference in their safety profile.
The present invention relates to an in-situ gel preparation for eyes, which has proper phase transition temperature. The advantages of solution and gel are combined, and the defects of solution and gel are avoided in the present invention. The combination of different types of poloxamer is used for preparing the in-situ gel preparation for eyes, which contains medicine and water-soluble high-molecular auxiliary material. The preparation contains poloxamer 407 and poloxamer 188, and water-soluble high-molecular auxiliary material whose concentration is less than 3% can also be added to the raw material. The in-situ gel has proper phase transition temperature, administration can be accomplished in a liquid state at room temperature, and gel is formed on the surface of a living cornea. The present invention can delay medicine removal, can improve local bioavailability and is suitable for various kinds of ophthalmic medicine.
Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.
The association between obstructive sleep apnea (OSA) and proteinuria is undetermined, with few studies on hypertension, a high-risk group for renal impairment. Therefore, we aimed to explore whether OSA is an independent risk factor for proteinuria in patients with hypertension. We investigated the cross-sectional association between OSA and proteinuria. Participants were divided into groups by apnea hypopnea index (AHI) category. Multivariable Logistic regression analysis was used to evaluate the association between OSA severity, objectively measured sleep dimensions, and proteinuria which is mainly defined by 24-h urine protein quantification > 300 mg/24 h. Sensitivity analyses were performed by excluding those with comorbidities (primary aldosteronism and homocysteine ≥ 15 μmol/L). Of the 2106 participants, the mean age was 47.57 ± 10.50 years, 67.2% were men, and 75.9% were OSA patients. In total participants, compared with those without OSA, patients with mild OSA, moderate OSA, and severe OSA showed 1.09 (95% CI 0.80-1.40), 1.24 (95% CI 0.89-1.74) and 1.47 (95% CI 1.04-2.08) fold risk for proteinuria with a trend test P trend < 0.05. Each 10-unit increase in the AHI, oxygen desaturation index (ODI), and time spent with oxygen saturation < 90% (T90) was found to be associated with 13%, 10%, and 2% higher likelihood of proteinuria in the crude model, significant in adjusted models. The more severe the OSA is, the higher the risk of proteinuria. AHI and T90 are independently associated with a higher risk of structural renal damage in the population with hypertension.
Patients will be treated with ribociclib (LEE011) (recommended phase 2 dose of 600 mg/day) for 8-21 days prior to surgery. For preliminary evaluation of efficacy and toxicity, patients with Rb-positive tumors will resume treatment with ribociclib at 14-28 days post-surgery on a schedule of 21 days on, 7 days off in a 28-day cycle. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics.
Women randomized to "new procedure group" will first undergo fetal weight ultrasound estimation at 38 weeks 0 days to 38 weeks 6 days of gestation, if the fetus is estimated to be LGA/macrosomia by ultrasound, women should have an elective induction of labor immediately (at 38 weeks 0 days to 38 weeks 6 days of gestation). On the contrary, if the fetus is estimated to be normal size, the pregnant women were then given a cervical assessment. If the Bishop score ≥6, women will have at least weekly follow-up visits with their doctors and unless a medical indication is present, continue pregnancy and have selective induction at 40 weeks 0 days of gestation. Whereas, if the Bishop score \<6, women will be followed up until 41 weeks 0 days of gestation with a close assessment of fetal wellbeing through the cardiotocographic trace. And women who will not deliver by this gestational age will be admitted for labor induction. Certainly, medical indication should warrant delivery without delay.
So far there is no convincing evidence that any treatment can be really effective in slowing or preventing the development of OA. The viscosupplementation by intraarticular injection of hyaluronate-derived products has gained popularity as a treatment modality of gonarthrosis. Today there are various papers on the treatment of gonarthrosis by intraarticular injection. Several methods have shown good results. There isn't, however, a consensus on the best method. The investigators know that in the treatment of osteoarthritis, with the viscosupplementation Hylan is superior in the long term, than the infiltration with cortisone. The good short term results achieved by infiltration of cortisone make us think about the combination of these drugs. The investigators will be assessing 104 patients with osteoarthritis of the knee, divided into two groups. Patients in group 1 will be subjected to infiltration procedure 6ml of Hylan. Patients in Group 2 will undergo the procedure of infiltration with 6ml of Hylan and 1ml (20mg) of hexacetonide Triamcinolone. The researcher will apply the informed consent term, the pain visual analog scale (VAS), WOMAC and Lequesne questionnaires. The questionnaires will be answered before infiltration (week zero), one week after the puncture (week 1), four weeks after (week 4) and 12 weeks after (week 12) and 24 weeks after (week 24).
The invention relates to a traditional Chinese medicine composition for treating cow endometritis and a preparation method thereof, belonging to the technical field of traditional Chinese veterinary medicine. The composition provided by the invention is mainly prepared from epimedium, actinolite, dodder, angelica, motherwort, prepared rehmannia root, rhizoma anemarrhenae, radix scutellariae, chuanxiong rhizome and semen allii tuberosi. The composition provided by the invention has the functions of resisting bacteria and diminishing inflammation, clearing away heat and toxic material, activating blood circulation to dissipate blood stasis, enriching the blood and the like. In the invention, all prescription components are pure natural medicinal materials which can not generate drug resistance, have no residues and no toxic side effects and are safe and effective. The composition provided by the invention has the advantages of simple preparation process and high drug content and is convenient and practical. The clinical test proves that the composition provided by the invention not only can be used for effectively treating cow endometritis but also has a good effect on treating apogeny caused by cow endometritis.
Patients were treated with diet, exercise, and/or oral conventional pharmacotherapy combined with insulin. Oral conventional pharmacotherapy consisted of α-glycosidase inhibitors (α-GI), sulfonylurea (SU), biguanide (BG), thiazolidinedione (TZD), or combinations of these agents. Insulin therapy consisted of subcutaneous injections of long-acting insulin analogues prior to sleep and bolus subcutaneous injections of rapid-acting insulin analogues in multiple daily injections, or subcutaneous injections of mixed insulin analogues twice a day. In spite of the treatments, when the physician in charge judged that their values of HbA1c were inappropriate, the physician added the pharmacotherapy combined the insulin to incretin-based therapy. 2.3.2. For ethical reasons, patients were treated with various anti-hypertensive, anti-diabetic, anti-dyslipidemia and/or anti-hypercoagulation agents during the course of the study by the patients' own doctors as a part of continuing standard medical care. As to the drugs that have been used for the treatment of other disorders and its complication since the time before the study, the content should not be changed during the study in principle unless the complication is cured. If any new complication occurs during the study period, an appropriate treatment is given by the judgment of investigator.
BACKGROUND: no-reflow can complicate up to 25% of pPCI and is associated with significant morbidity and mortality. We aimed to compare the outcomes of intracoronary epinephrine and verapamil with intracoronary adenosine in the treatment of no-reflow after primary percutaneous coronary intervention (pPCI).
METHODS: 108 STEMI patients had no-reflow during pPCI were assigned into four groups. Group 1, in which epinephrine and verapamil were injected through a well-cannulated guiding catheter. Group 2, in which same drugs were injected in the distal coronary bed through a microcatheter or perfusion catheter. Group 3, in which adenosine was injected through a guiding catheter. Group 4, in which adenosine was injected in distal coronary bed. Primary end point was the achievement of TIMI III flow and MBG II or III. Secondary end point was major adverse cardiovascular and cerebrovascular events (MACCEs) during hospital stay.
RESULTS: The study groups did not differ in their baseline characteristics. Primary end point was achieved in 15 (27.8%) patients in the guide-delivery arm compared with 34 (63%) patients in the local-delivery arm, p < 0.01. However, the primary end point did not differ between the epinephrine/verapamil group and the adenosine group (27 (50%) vs 22 (40.7%), p = 0.334). The secondary end points were similar between the study groups.
CONCLUSION: Local delivery of epinephrine, verapamil and adenosine in the distal coronary bed is more effective in achieving TIMI III flow with MBG II or III compared with their guide-delivery in patients who suffered no-reflow during pPCI. There was no difference between epinephrine/verapamil Vs. adenosine.
The CrosserTM CTO Recanalization Catheter ("Crosser system") (Bard Peripheral Vascular Inc. Tempe, AZ, USA), which serves as a control in this investigation, gained U.S. FDA approval for peripheral indications in 2011. The device is similar in both design and indications to the TruePath device, with the exception that the Crosser system uses vibrational angioplasty to achieve CTO crossing.
A method of verifying that a user 10 has performed an action related to an item 12, such as using a Covid-19 testing kit. A recordal system database stores a user record 21 along with a user ID 24 issued to the user as a graphical machine-readable indicium such as a two-dimensional barcode. An item ID 26 is allocated to and accompanies the physical item, also embodied as a graphical machine-readable indicium. For example, an adhesive label bearing a two-dimensional barcode may be applied to a testing kit, its packaging, or accompanying paperwork. Video 29 is captured showing the user performing the action related to the item, such as using the Covid-19 testing kit, and also including an image of the item ID. The video is transmitted to an authorised party 22b alongside the user ID. The authorised party verifies the user is seen performing the action in the video, and is authenticated to access the user’s record in the recordal system under rules of authentication in which the physical item is paired to the user. To create or amend a record of using the item 14, the authorised party must provide the paired item ID and user ID.
Patients receive ropidoxuridine PO QD over 7 days per week and capecitabine PO BID over 6 days per week for 6 weeks. Patients also undergo radiation therapy over 1 fraction per day for 5 days per week (Monday-Friday) during weeks 1-5 and for 3 days during week 6 in the absence of disease progression or unacceptable toxicity. Approximately 8-12 weeks after completion of treatment with ropidoxuridine, capecitabine, and radiation therapy, patients undergo standard of care surgery.
1411422 Purifying urokinase solutions CHOAY SA 22 Sept 1972 [24 Sept 1971 30 June 1972 (2)] 15502/75 Divided out of 1411421 Heading C3H A method of purifying an aqueous solution containing 1.5-3 mg./ml. of urokinase, foreign proteins and pyrogenic substances involves adjusting the pH of the solution to between 3 and 4.5 and its conductivity to between 15,000 and 25,000 micromhos/cm., determining, e.g. with the aid of a graph prepared from experimental results, the concentration of ammonium suplate needed for forming a precipitate of foreign proteins &c. containing only 2-5% of the total activity of the urokinase in the initial solution, adding to the solution the appropriate quantity of ammonium sulphate and collecting the supernatant. The concentration of ammonium sulphate employed should preferably correspond to a degree of saturation of the solution of from 0.25 to 0.35. The urokinase is then precipitated out with a further quantity of ammonium sulphate and the precipitate is dissolved in distilled, sterile apyrogenic water at pH 7. The initial urokinase solution may be obtained from human urine by absorbing the proteins &c. from the urine on a filtration adjuvant, re-extracting the urokinase and other adsorbed proteins &c. therefrom, salting out urokinase from the solution by adding ammonium sulphate, dissolving the resulting precipitate in a glucose solution and dialysing the latter to obtain a concentrated crudeurokinase solution of specified conductivity, two steps of fractionation using diethylaminoethyl cellulose employing in the first step solutions of pH 4-6 and conductivity 15,000- 25,000 micromhos/cm. with 15-40 g. of resin per 14 million CTA units of urokinase, and in the second step solutions of pH 6-7 and conductivity 15,000-18,000 micromhos/cm. with 30-60 g. of resin per 10 million CTA units of the enzyme, the urokinase-containing medium during the second step being diluted with quantities of water sufficient to lower the conductivity by about 1000 micromhos/cm. at each successive dilution until a conductivity of about 9000 micromhos/cm. is reached, and then absorbing the urokinase in the solution obtained by combining the effluent and the washing liquors from the resin used in the second fractionation on either carboxymethyl cellulose at a pH of about 5 and eluting the adsorbed urokinase using a phosphate buffer at pH 6.8-6.9, or kaolin at pH 6.2 and eluting the urokinase retained with a solution of ammonium chloride in 4% ammonia, followed by precipitation with ammonium sulphate and dialysis against a 0.05 M phosphate solution buffered to pH 6.2.
NEW MATERIAL:The platinum (II) complex of formula I (X2 is anion corresponding to bivalent) and its oxidized complex. EXAMPLE:Oxidized product of platinum-ethyleneurea complex of formula II. USE:Carcinostatic agent. PROCESS:cis-Diammine diaqua platinum nitrate is prepared by the dechlorination reaction of cis-diammine platinum dichloride with an aqueous solution of a nitrate. The obtained salt is added with an aqueous solution of a cyclic lower alkyleneurea, and the mixture is adjusted to 7 pH with an aqueous solution of ammonia, stirred at about room temperature, and cooled, concentrated or mixed with an insoluble solvent to precipitate the complex of formula I , which is separated from the mixture and dried. If necessary, the complex is oxidized in an aqueous solution of 7 pH with an oxidizing agent such as persulfate to obtain the oxidized product of the above complex.
Cervical cancer cases continue to rise despite all the advanced screening and preventative measures put in place, which include human papillomavirus (HPV) vaccination. These soaring numbers can be attributed to the lack of effective anticancer drugs against cervical cancer; thus, repurposing the human immunodeficiency virus protease inhibitors is an attractive innovation. Therefore, this work was aimed at evaluating the potential anticancer activities of HIV-PIs against cervical cancer cells. The MTT viability assay was used to evaluate the effect of HIV protease inhibitors on the viability of cervical cancer cells (HeLa) and non-cancerous cells (HEK-293). Further confirmation of the MTT assay was performed by confirming the IC50s of these HIV protease inhibitors on cervical cancer cells and non-cancerous cells using the Muse™ Count and Viability assay. To confirm the mode of death induced by HIV protease inhibitors in the HPV-associated cervical cancer cell line, apoptosis was performed using Annexin V assay. In addition, the Muse™ Cell Cycle assay was used to check whether the HIV protease inhibitors promote or halt cell cycle progression in cervical cancer cells. HIV protease inhibitors did not affect the viability of non-cancerous cells (HEK-293), but they decreased the viability of HeLa cervical cancer cells in a dose-dependent manner. HIV protease inhibitors induced apoptosis in HPV-related cervical cancer cells. Furthermore, they also induced cell cycle arrest, thus halting cell cycle progression. Therefore, the use of HIV drugs, particularly HIV-1 protease inhibitors, as potential cancer therapeutics represents a promising strategy. This is supported by our study demonstrating their anticancer properties, notably in HPV-associated cervical cancer cell line.